PRMT5 and breast carcinoma: PRMT5 regulates BRCA1 mRNA stability by promoting nuclear translocation of ALKBH5, which demethylates BRCA1 transcripts under doxorubicin treatment, thereby enhancing repair capacity and reducing chemotherapy efficacy in breast cancer cells (Fig. 7B) [527].